| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.93.2.215 |
| P698 | PubMed publication ID | 8548891 |
| P2093 | author name string | A Itoh | |
| S Nakamura | |||
| A Colombo | |||
| G Martini | |||
| P Hall | |||
| M Ferraro | |||
| S Blengino | |||
| L Maiello | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aspirin | Q18216 |
| P304 | page(s) | 215-222 | |
| P577 | publication date | 1996-01-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation | |
| P478 | volume | 93 |
| Q28194376 | A guide to drug use during percutaneous coronary intervention |
| Q73913260 | A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation |
| Q58976304 | ACC expert consensus document on coronary artery stents |
| Q33699882 | Advances in antithrombotic therapy of acute myocardial infarction |
| Q24793199 | Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention |
| Q73407496 | Antiplatelet effect of ticlopidine after coronary stenting |
| Q73249498 | Antiplatelet rather than anticoagulant therapy with coronary stenting |
| Q41343897 | Antiplatelet therapy following stent deployment. |
| Q33805244 | Antiplatelet therapy in interventional cardiology: I. Newer oral antiplatelet agents |
| Q33331052 | Antiplatelet therapy in interventional cardiology: II. Glycoprotein IIb/IIIa inhibitors |
| Q35368874 | Antiplatelet treatment with cilostazol after stent implantation. |
| Q48294670 | Aortic Source of Brain Embolism |
| Q28192340 | Aspirin alone antiplatelet regimen after intracoronary placement of the Carbostent: the ANTARES study |
| Q33329240 | Aspirin and ticlopidine after routine coronary stenting: the gold standard as of 1999. |
| Q74562163 | Clinical and angiographic outcome of Micro Stent II implantation in native coronary arteries |
| Q74562161 | Clinical outcome at six months of coronary stenting followed by ticlopidine monotherapy |
| Q42325413 | Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention: clinical and cost-effectiveness analyses |
| Q28167263 | Clopidogrel induced urticarial rash in a patient with left main stem percutaneous coronary intervention: management issues |
| Q73250221 | Clopidogrel versus ticlopidine after intracoronary stent placement |
| Q34030132 | Clopidogrel: a review of its use in the prevention of atherothrombosis |
| Q71774931 | Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting |
| Q51748167 | Comparison of prasugrel and bivalirudin vs clopidogrel and heparin in patients with ST-segment elevation myocardial infarction: Design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial. |
| Q41139302 | Contemporary stent designs: technical considerations, complications, role of intravascular ultrasound, and anticoagulation therapy |
| Q33795842 | Coronary artery stents: appropriate use of adjunctive pharmacotherapy to prevent stent thrombosis |
| Q73227467 | Coronary stenting (Cordis) without anticoagulation |
| Q28210958 | Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation |
| Q28193665 | Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial) |
| Q73022264 | Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting |
| Q28176380 | Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators |
| Q35583183 | Findings of intravascular ultrasound during acute stent thrombosis. |
| Q44360397 | Frequency of adverse clinical events in the 12 months following successful intracoronary stent placement in patients treated with aspirin and ticlopidine (without warfarin). |
| Q28168060 | Guidelines on the management of secondary prophylaxis of vascular events in stable patients in primary care |
| Q44421477 | Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: Do we need more aggressive dosing regimens in unstable angina? |
| Q40846150 | Impact of intravascular ultrasound guidance in stent deployment on 6-month restenosis rate: a multicenter, randomized study comparing two strategies--with and without intravascular ultrasound guidance. RESIST Study Group. REStenosis after Ivus guide |
| Q73046990 | Interventions in cardiology: what does and does not work |
| Q35369510 | Intracoronary Multi-link stents: experience in 218 patients using aspirin alone |
| Q71870003 | Intracoronary stenting using slotted tubular stents with intravascular ultrasound and anticoagulation |
| Q71696152 | Intracoronary stents |
| Q77990238 | Intravascular ultrasound-guided balloon angioplasty for treatment of in-stent restenosis |
| Q36836931 | Intravascular ultrasound-guided emergency coronary Palmaz-Schatz stent placement without post-procedural systemic anticoagulation |
| Q35376903 | Is provisional stenting the effective option? The WIDEST study (Wiktor stent in de novo stenosis). Widest Trial Investigators' Group |
| Q34051300 | Ischemic complications after percutaneous transluminal coronary angioplasty |
| Q30305538 | Management of Acute Ischemic Coronary Syndromes: The Present and Future |
| Q35847529 | Modulating thrombotic potential in catheter-based percutaneous coronary and peripheral vascular interventions |
| Q34306764 | New developments in percutaneous coronary intervention |
| Q28182051 | New polycyclic pyrimidine derivatives with antiplatelet in vitro activity: synthesis and pharmacological screening |
| Q35199720 | Oral platelet glycoprotein IIb/IIIa receptor inhibitors--Part I. |
| Q56928579 | Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial |
| Q73028181 | Outpatient coronary stent implantation |
| Q46523104 | Overview of advances in cardiovascular disease treatment and prevention: the evolving role of antiplatelet therapy |
| Q38107887 | Patients who require non-cardiac surgery in acute coronary syndrome |
| Q30323095 | Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the BElgian NEtherlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and |
| Q73681288 | Platelet Inhibition in Cardiovascular Disease Management: Aspirin and Beyond |
| Q73186321 | Practice guidelines of the Spanish Society of Cardiology. Recommendations for the use of antithrombotic treatment in cardiology |
| Q61669170 | Pretreatment With Aspirin and Ticlopidine Confers Lower Thrombogenic Potential of Radiofrequency Catheter Ablation |
| Q35367053 | Procedural and follow up results with a new balloon expandable stent in unselected lesions. |
| Q56945137 | Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade |
| Q50984590 | Reduction of thrombotic and hemorrhagic complications after stent implantation. |
| Q78200462 | Results of coronary stenting after delayed angioplasty of the culprit vessel in patients with recent myocardial infarction |
| Q24792611 | Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement? |
| Q73591638 | Safety and efficacy of angiography-guided stent placement in small native coronary arteries of < 3.0 mm in diameter |
| Q28195429 | Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention |
| Q30426905 | Single device approach to ultrasound-guided percutaneous transluminal coronary angioplasty and stenting: initial experience with a combined intracoronary ultrasound/variable diameter balloon |
| Q34007532 | Stent thrombosis: historical perspectives and current trends |
| Q41073641 | Subacute stent thrombosis and the anticoagulation controversy: changes in drug therapy, operator technique, and the impact of intravascular ultrasound. |
| Q71975646 | Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome |
| Q37900470 | The evolution of antiplatelet therapy in cardiovascular disease |
| Q28186354 | The role of adenosine 5'-diphosphate receptor blockade in patients with cardiovascular disease |
| Q33392895 | The safety of clopidogrel |
| Q34027299 | The thienopyridines in coronary artery disease |
| Q74587202 | Ticlopidine after stenting: "Render unto Caesar that which belongs to Caesar" |
| Q73254330 | Ticlopidine enhances the platelet inhibitory capacity of abciximab in vitro |
| Q41751922 | Ticlopidine-induced neutropenia mimicking sepsis early after intracoronary stent placement |
| Q40905157 | Ultrasound-guided stent placement |
| Q73420698 | Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen |
| Q33330996 | Usefulness of cilostazol versus ticlopidine in coronary artery stenting |
| Q28194741 | Utility of platelet adp receptor antagonism in the emergency department: a review |
| Q94558111 | Value of Antiplatelet Therapy in Preventing Thrombotic Events in Generalized Vascular Disease |
| Q28196407 | What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention? |
| Q74178813 | [Subacute thrombosis with antiplatelet treatment in a non-selected population of intracoronary stents: incidence and predictors] |
Search more.